Canada's Perimeter Medical Imaging prelim Q4 revenue jumps 143%

Perimeter Medical Imaging AI

31/03/2026 21:35

Overview

Canada medical imaging firm's preliminary Q4 revenue rose 143% yr/yr to record high

Preliminary Q4 net loss narrowed 42% yr/yr as operating expenses fell sharply

Company received FDA PMA approval for Claire OCT device, U.S. launch planned for Q2-2026

Outlook

Perimeter expects growing installed base and consumable sales to drive sustained revenue growth

Result Drivers

S-SERIES OCT ADOPTION - Q4 revenue growth driven by increased commercial adoption and utilization of S-Series OCT platform

OPERATING EXPENSES - Q4 operating expenses fell 46% yr/yr, contributing to narrower net loss

Company press release: ID:nPn7ns6lCa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
-$0.02
Q4 Net Income
-$2 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Perimeter Medical Imaging AI Inc is C$1.50, about 265.9% above its March 30 closing price of C$0.41

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)